Patient, donor, and graft characteristics
No. patients | 116* |
Median patient age (range) | 38 yrs (17-61) |
Patient sex (male/female) | 58/58 |
Diagnosis | |
Leukemia/myelodysplastic syndrome | 66 |
Lymphoma/Hodgkin disease/myeloma | 42 |
Solid tumor | 8 |
Disease status | |
First remission or chronic phase | 12 |
Second remission or accelerated phase | 31 |
Relapse or blast crisis | 73 |
Preparative regimen | |
Total body irradiation–based | 30 |
Chemotherapy alone | 86 |
GVHD prophylaxis | |
Cyclosporine/methylprednisolone | 32 |
Tacrolimus/methylprednisolone | 45 |
Tacrolimus/methotrexate | 39 |
Prior grades 2-4 acute GVHD | 33 |
On steroids at day 100 | 46 |
Median donor age (range) | 39 yrs (8-64) |
Donor sex (male/female) | 57/59 |
Pair cytomegalovirus-seronegative | 12 |
Total nucleated cells infused (range) | 8.7 × 108/kg (1.1-26.3) |
CD34+ cells infused (range) | 5.7 × 106/kg (1.9-20.9) |
CD3+ cells infused (range) | 2.3 × 108/kg (0.3-6.9) |
CD56+cells infused (range) | 2.6 × 107/kg (1.0-8.1) |
No. patients | 116* |
Median patient age (range) | 38 yrs (17-61) |
Patient sex (male/female) | 58/58 |
Diagnosis | |
Leukemia/myelodysplastic syndrome | 66 |
Lymphoma/Hodgkin disease/myeloma | 42 |
Solid tumor | 8 |
Disease status | |
First remission or chronic phase | 12 |
Second remission or accelerated phase | 31 |
Relapse or blast crisis | 73 |
Preparative regimen | |
Total body irradiation–based | 30 |
Chemotherapy alone | 86 |
GVHD prophylaxis | |
Cyclosporine/methylprednisolone | 32 |
Tacrolimus/methylprednisolone | 45 |
Tacrolimus/methotrexate | 39 |
Prior grades 2-4 acute GVHD | 33 |
On steroids at day 100 | 46 |
Median donor age (range) | 39 yrs (8-64) |
Donor sex (male/female) | 57/59 |
Pair cytomegalovirus-seronegative | 12 |
Total nucleated cells infused (range) | 8.7 × 108/kg (1.1-26.3) |
CD34+ cells infused (range) | 5.7 × 106/kg (1.9-20.9) |
CD3+ cells infused (range) | 2.3 × 108/kg (0.3-6.9) |
CD56+cells infused (range) | 2.6 × 107/kg (1.0-8.1) |
No. patients unless indicated otherwise.